Dr. Richard K. Valicenti, MD

Dr. Valicenti practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Valicenti's NPI, 1235152232, was assigned on July 25, 2006. Dr. Valicenti graduated from Drexel University College Of Medicine in 1990. Dr. Valicenti holds California license G88442.

Dr. Valicenti's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Valicenti's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Valicenti is also affiliated with Adventist Health and Rideout. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Valicenti to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Valicenti practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Valicenti's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Valicenti is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Valicenti's licenses on file in 3 states: California, Pennsylvania and New Jersey.

Dmand AI lists colorectal cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Valicenti treats.

CMS data shows 2,635 Medicare services from Dr. Valicenti across 20 procedure codes in 2024, for 359 Medicare patients. Medicare paid $205,676 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 359 Medicare patients who saw Dr. Valicenti in 2024. The largest group is 65 to 74, with 170 patients. 75% of them have cancer, and 74% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.38, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Valicenti's median patient age at 71, with 6% women.

In 2024, Dr. Valicenti wrote 94 Medicare Part D claims for 33 patients. 100% of them were for generic drugs. CMS names the drug for 85 of them, across 2 drugs with 11 or more claims each, at $1,790 in total drug cost. In 2023, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Valicenti for performance year 2024, reported as part of a group. Dr. Valicenti accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Valicenti as offering telehealth.

Dmand AI links 100 papers to Dr. Valicenti, published from 2006 to 2025. 2019 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Radiotherapy Dosage. Dr. Valicenti has published most often in Int J Radiat Oncol Biol Phys. Dr. Valicenti's most frequent co-authors are Leonard G. Gomella, MD, Jyoti S. Mayadev, MD and Adam P. Dicker, MD.

Dmand AI links Dr. Valicenti to 14 clinical trials, 6 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urinary Bladder Neoplasms. NRG Oncology sponsors the most, 6.

CMS Open Payments shows 47 general payments to Dr. Valicenti from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $5,888.

Dmand AI lists 4 awards for Dr. Valicenti, most recently Best Doctor of America in 2019.

Dr. Valicenti graduated from Drexel University College Of Medicine in 1990.

Dr. Valicenti is in network with 6 carriers, including Aetna, United Healthcare and Blue Cross and Blue Shield of Kansas City. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.